Nurix Therapeutics, Inc. Common stock (NRIX) is a publicly traded Healthcare sector company. As of May 21, 2026, NRIX trades at $16.03 with a market cap of $1.60B and a P/E ratio of -5.12. NRIX moved +8.01% today. Year to date, NRIX is -6.12%; over the trailing twelve months it is +61.93%. Its 52-week range spans $8.18 to $29.56. Analyst consensus is strong buy with an average price target of $30.43. Rallies surfaces NRIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes NRIX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $16.03 |
| Market Cap | $1.60B |
| P/E Ratio | -5.12 |
| EPS | $-3.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.56 |
| 52-Week Low | $8.18 |
| Volume | 1.50M |
| Avg Volume | 0 |
| Revenue (TTM) | $71.78M |
| Net Income | $-295.28M |
| Gross Margin | 0.00% |
8 analysts cover NRIX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.43.